Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.86 |
| ▸ | GAK | O14976 | 4/20 | 0.71 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | BUB1 | O43683 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.57 |
| ▸ | STK17B | O94768 | 1/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131741 | 0.90 | EGFR (0.72) | EGFRERBB2GAKSRC | |
| SCHEMBL29670932 | 0.90 | EGFR (0.72) | EGFRERBB2GAKSRC | |
| SCHEMBL30132269 | 0.90 | EGFR (0.72) | EGFRERBB2GAKSRC | |
| SCHEMBL2943166 | 0.90 | EGFR (0.85) | EGFRERBB2GAKSRCRAF1 | |
| SCHEMBL9911504 | 0.88 | EGFR (0.68) | EGFRERBB2GAKSRC | |
| SCHEMBL3594390 | 0.88 | EGFR (0.86) | EGFRERBB2GAKSRC | |
| SCHEMBL14391855 | 0.88 | EGFR (0.86) | EGFRERBB2GAKSRCPLK4 | |
| SCHEMBL14391932 | 0.86 | EGFR (0.86) | EGFRERBB2GAKSRCPLK4 | |
| SCHEMBL22419601 | 0.84 | EGFR (0.71) | EGFRERBB2GAKSRC | |
| SCHEMBL12094777 | 0.82 | EGFR (0.59) | EGFRERBB2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885ERBB2 199/4885GAK 114/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885GAK 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.